Breaking News Instant updates and real-time market news.

AVXS

AveXis

$47.51

2.35 (5.20%)

15:38
10/09/16
10/09
15:38
10/09/16
15:38

AveXis reports interim Phase 1 data on AVXS-101 in spinal muscular atrophy

AveXis provided an update on interim data from the ongoing Phase 1 trial of AVXS-101 in spinal muscular atrophy Type 1 as of September 15. The data were presented at the 21st International Annual Congress of the World Muscle Society. "For the first time, interim data from the trial were presented that highlighted patient achievement of key motor development milestones as of September 15. Two-thirds of patients in Cohort 2 - the proposed therapeutic dose - had achieved the ability to sit unassisted, including one patient whose achievement of this milestone was confirmed after September 15. In Cohort 2, 11 of 12 patients achieved head control, 7 of 12 patients could roll over completely and 11 of 12 patients could sit with support. Two patients are now walking independently, including one whose achievement of this milestone was confirmed after September 15. These two patients each achieved earlier and important developmental milestones such as crawling, standing with support, standing alone and walking with support," the company said. Data as of September 15 showed AVXS-101 continued to demonstrate a favorable safety profile and was generally well tolerated, with no new treatment-related safety or tolerability concerns identified.

  • 06

    Nov

AVXS AveXis
$47.51

2.35 (5.20%)

09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
10/06/16
GSCO
10/06/16
NO CHANGE
Target $71
GSCO
Buy
AveXis attractive acquisition target, price target to $71 at Goldman
Goldman analyst Salveen Richter said AveXis has two approaching catalysts coming up, the AVXS-101 update in SMA Type 1 at the World Muscle Society, or WMS, on October 8, and clarity on the AVXS-101 pivotal trial design in late October/early November. The analyst expects positive WMS data and raaised his probability of success to 60% from 45%. He expects compelling motor milestone data and pivotal trial visibility to make AveXis an attractive acquisition target and raised his price target to $71 from $46 on shares and reiterated his Buy rating.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).

TODAY'S FREE FLY STORIES

AKS

AK Steel

$7.12

0.4 (5.95%)

08:37
04/25/17
04/25
08:37
04/25/17
08:37
Earnings
AK Steel reports Q1 EPS 19c, consensus 15c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    May

MBII

Marrone Bio

$1.75

-0.02 (-1.13%)

08:35
04/25/17
04/25
08:35
04/25/17
08:35
Syndicate
Marrone Bio 5.71M share Spot Secondary priced at $1.40 »

National Securities Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

TBPH

Theravance Biopharma

$39.21

0.42 (1.08%)

08:35
04/25/17
04/25
08:35
04/25/17
08:35
Hot Stocks
Theravance Biopharma presented data from studies of VIBATIV »

Theravance Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

DD

DuPont

$79.37

0.72 (0.92%)

, INTC

Intel

$36.75

0.43 (1.18%)

08:35
04/25/17
04/25
08:35
04/25/17
08:35
Conference/Events
Senate Judiciary Committee to hold a hearing »

The Committee holds a…

DD

DuPont

$79.37

0.72 (0.92%)

INTC

Intel

$36.75

0.43 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 31

    May

08:35
04/25/17
04/25
08:35
04/25/17
08:35
General news
Bullish momentum on U.S. equities »

Bullish momentum on U.S.…

IBM

IBM

$160.75

0.37 (0.23%)

, GSK

GlaxoSmithKline

$41.12

0.34 (0.83%)

08:34
04/25/17
04/25
08:34
04/25/17
08:34
Hot Stocks
The Weather Company renews collaboration with GSK Consumer Healthcare »

The Weather Company, an…

IBM

IBM

$160.75

0.37 (0.23%)

GSK

GlaxoSmithKline

$41.12

0.34 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 07

    May

  • 06

    Jun

ECOM

ChannelAdvisor

$11.65

-0.1 (-0.85%)

, EBAY

eBay

$32.05

-0.13 (-0.40%)

08:34
04/25/17
04/25
08:34
04/25/17
08:34
Hot Stocks
ChannelAdvisor announces strategic partnership with eBay »

ChannelAdvisor…

ECOM

ChannelAdvisor

$11.65

-0.1 (-0.85%)

EBAY

eBay

$32.05

-0.13 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 18

    May

MRVL

Marvell

$15.06

0.16 (1.07%)

, AVGO

Broadcom

$221.24

3.58 (1.64%)

08:34
04/25/17
04/25
08:34
04/25/17
08:34
Hot Stocks
Marvell appoints Neil Kim as CTO »

Marvell (MRVL) announced…

MRVL

Marvell

$15.06

0.16 (1.07%)

AVGO

Broadcom

$221.24

3.58 (1.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$45.90

1.81 (4.11%)

08:34
04/25/17
04/25
08:34
04/25/17
08:34
Hot Stocks
Sanofi: Aubagio had significant effect on reducing cortical gray matter atrophy »

Sanofi Genzyme, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 03

    May

IMMR

Immersion

$8.66

0.18 (2.12%)

08:33
04/25/17
04/25
08:33
04/25/17
08:33
Hot Stocks
Immersion signs multiyear license renewal with ALPS »

Immersion Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$907.41

8.88 (0.99%)

08:33
04/25/17
04/25
08:33
04/25/17
08:33
Periodicals
Amazon opens Amazon Global Selling office in Taiwan, DigiTimes says »

Amazon has opened an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 16

    May

  • 23

    May

PZRX

PhaseRx

$1.91

0.67 (54.03%)

08:33
04/25/17
04/25
08:33
04/25/17
08:33
Hot Stocks
PhaseRx receives 'positive' opinion for orphan drug designation for PRX-OTC »

PhaseRx announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDTX

Cidara Therapeutics

$7.20

0.15 (2.13%)

08:32
04/25/17
04/25
08:32
04/25/17
08:32
Hot Stocks
Cidara Therapeutics promotes Taylor sandison to chief medical officer »

Cidara Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMPI

DelMar Pharmaceuticals

$2.70

-0.1 (-3.57%)

08:32
04/25/17
04/25
08:32
04/25/17
08:32
Hot Stocks
DelMar Pharma enters into collaboration with Duke University for VAL-083 »

DelMar Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSIS

OSI Systems

$72.27

0.63 (0.88%)

08:31
04/25/17
04/25
08:31
04/25/17
08:31
Hot Stocks
OSI Systems awarded $7M contract to provide checkpoint inspection systems »

OSI Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 06

    Jun

BNED

Barnes & Noble Education

$10.38

0.08 (0.78%)

08:31
04/25/17
04/25
08:31
04/25/17
08:31
Hot Stocks
Barnes & Noble Education names Michael Miller chief legal officer »

Barnes & Noble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

08:31
04/25/17
04/25
08:31
04/25/17
08:31
Options
One option delisting on April 25th »

Option delistings…

LLY

Eli Lilly

$83.42

1.53 (1.87%)

08:30
04/25/17
04/25
08:30
04/25/17
08:30
Technical Analysis
Eli Lilly trades lower after earnings and outlook »

The shares were last…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 07

    May

  • 31

    May

BIDU

Baidu

$180.03

1.95 (1.10%)

, NFLX

Netflix

$143.83

0.96 (0.67%)

08:28
04/25/17
04/25
08:28
04/25/17
08:28
Technical Analysis
Netflix edges up to 52-week highs in pre-market trading »

Shares were last at…

BIDU

Baidu

$180.03

1.95 (1.10%)

NFLX

Netflix

$143.83

0.96 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 05

    Jun

ANTM

Anthem

$168.41

0.61 (0.36%)

, ESRX

Express Scripts

$67.25

0.79 (1.19%)

08:28
04/25/17
04/25
08:28
04/25/17
08:28
Recommendations
Anthem, Express Scripts analyst commentary  »

Anthem contract…

ANTM

Anthem

$168.41

0.61 (0.36%)

ESRX

Express Scripts

$67.25

0.79 (1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 18

    May

  • 06

    Jun

WAT

Waters

$160.27

1.75 (1.10%)

08:26
04/25/17
04/25
08:26
04/25/17
08:26
Earnings
Waters sees FY17 EPS $7.20-$7.40, consensus $7.04 »

Sees a mid single digit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

AAPL

Apple

$143.64

1.37 (0.96%)

, CBS

CBS

$65.95

-0.89 (-1.33%)

08:25
04/25/17
04/25
08:25
04/25/17
08:25
Periodicals
Apple Music delays release of first series 'Carpool Karaoke,' Reuters reports »

Apple's Apple Music…

AAPL

Apple

$143.64

1.37 (0.96%)

CBS

CBS

$65.95

-0.89 (-1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 04

    May

  • 15

    Jun

WAT

Waters

$160.27

1.75 (1.10%)

08:25
04/25/17
04/25
08:25
04/25/17
08:25
Earnings
Waters sees Q2 EPS $1.65-$1.75, consensus $1.67 »

Sees strong mid-single…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

08:25
04/25/17
04/25
08:25
04/25/17
08:25
Conference/Events
The Washington Journal holds a discussion on Dodd-Frank »

Manhattan Institute…

WHR

Whirlpool

$174.80

3.29 (1.92%)

08:22
04/25/17
04/25
08:22
04/25/17
08:22
Hot Stocks
Whirlpool sees 3%-5% annual organic net sales growth, 10%+ EBIT margin by 2020 »

Says fundamentals of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.